Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

92.63
Delayed Data
As of 3:59pm ET
 +3.00 / +3.35%
Today’s Change
76.02
Today|||52-Week Range
102.49
+11.82%
Year-to-Date
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?
10:52am / Zacks.com - Paid Partner Content
BioMarin (BMRN) in Focus: Stock Moves 7% Higher
Jun 22 / Zacks.com - Paid Partner Content
Quick Tips on Investing in the Pharmaceutical and Medical Device Industry
Jun 25 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close89.63
Today’s open90.39
Day’s range89.09 - 92.89
Volume1,838,113
Average volume (3 months)1,187,546
Market cap$15.6B
Dividend yield--
Data as of 3:59pm ET, 06/28/2017

Growth & Valuation

Earnings growth (last year)-256.07%
Earnings growth (this year)+78.61%
Earnings growth (next 5 years)+127.00%
Revenue growth (last year)+27.18%
P/E ratioNM
Price/Sales12.40
Price/Book5.59

Competitors

 Today’s
change
Today’s
% change
PRGOPerrigo Company PLC+1.80+2.41%
MYLMylan NV+0.64+1.67%
JAZZJazz Pharmaceuticals...+0.32+0.21%
ALKSAlkermes Plc+1.04+1.82%
Data as of 4:15pm ET, 06/28/2017

Financials

Next reporting dateAugust 2, 2017
EPS forecast (this quarter)-$0.21
Annual revenue (last year)$1.1B
Annual profit (last year)-$630.2M
Net profit margin-56.74%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts